Literature DB >> 23537707

Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.

Charles O Brown1, Jeanine Schibler, Matthew P Fitzgerald, Neeraj Singh, Kelley Salem, Fenghuang Zhan, Apollina Goel.   

Abstract

This study evaluates the role of scavenger receptor class A member 3 (SCARA3) in multiple myeloma (MM). SCARA3 expression was induced upon treatment with oxidative stressors (ionizing radiation and chemotherapeutic drugs). An epigenetic inactivation of SCARA3 was noted in MM.1S myeloma cells. Myeloma cell killing by dexamethasone and bortezomib was inhibited by up-regulation of SCARA3 while SCARA3 knockdown sensitized myeloma cells to the drugs. Clinical samples showed an inverse correlation between SCARA3 gene expression, myeloma progression, and favorable clinical prognosis. In MM, SCARA3 protects against oxidative stress-induced cell killing and can serve as predictor of MM progression and therapeutic response. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23537707      PMCID： PMC3700682          DOI： 10.1016/j.leukres.2013.03.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  39 in total

Review 1.  Biochemistry and cell biology of mammalian scavenger receptors.

Authors:  Jane E Murphy; Philip R Tedbury; Shervanthi Homer-Vanniasinkam; John H Walker; Sreenivasan Ponnambalam
Journal:  Atherosclerosis       Date:  2005-09       Impact factor: 5.162

2.  CSR1 suppresses tumor growth and metastasis of prostate cancer.

Authors:  Guoying Yu; George C Tseng; Yan Ping Yu; Tim Gavel; Joel Nelson; Alan Wells; George Michalopoulos; Demetrius Kokkinakis; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

3.  CSR, a scavenger receptor-like protein with a protective role against cellular damage causedby UV irradiation and oxidative stress.

Authors:  H J Han; T Tokino; Y Nakamura
Journal:  Hum Mol Genet       Date:  1998-06       Impact factor: 6.150

Review 4.  Redox signaling in cancer biology.

Authors:  David Gius; Douglas R Spitz
Journal:  Antioxid Redox Signal       Date:  2006 Jul-Aug       Impact factor: 8.401

5.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Authors:  George Mulligan; Constantine Mitsiades; Barb Bryant; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David Schenkein; Dixie-Lee Esseltine; Anthony Boral; Kenneth C Anderson
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

6.  Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C: a role for oxidative stress.

Authors:  M Mietus-Snyder; A Friera; C K Glass; R E Pitas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-05       Impact factor: 8.311

7.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

8.  Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma.

Authors:  Irfan Kuku; Ismet Aydogdu; Nihayet Bayraktar; Emin Kaya; Omer Akyol; M Ali Erkurt
Journal:  Cell Biochem Funct       Date:  2005 Jan-Feb       Impact factor: 3.685

9.  Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma.

Authors:  T Zima; I Spicka; S Stípek; J Crkovská; J Pláteník; M Merta; V Tesar
Journal:  Neoplasma       Date:  1996       Impact factor: 2.575

10.  Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.

Authors:  Irfan Kuku; Mehmet Refik Bayraktar; Emin Kaya; Mehmet Ali Erkurt; Nihayet Bayraktar; Kerim Cikim; Ismet Aydogdu
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711
View more
  15 in total

1.  PepFect14 Signaling and Transfection.

Authors:  Luca Falato; Maxime Gestin; Ülo Langel
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

3.  Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response.

Authors:  Cassie Bennett; Farrah Mohammed; Anabel Álvarez-Ciara; Michelle A Nguyen; W Dalton Dietrich; Suhrud M Rajguru; Wolfgang J Streit; Abhishek Prasad
Journal:  Biomaterials       Date:  2018-10-18       Impact factor: 12.479

Review 4.  Oxidative stress and proteasome inhibitors in multiple myeloma.

Authors:  Brittany C Lipchick; Emily E Fink; Mikhail A Nikiforov
Journal:  Pharmacol Res       Date:  2016-01-29       Impact factor: 7.658

5.  Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.

Authors:  Adil Doganay Duru; Tolga Sutlu; Ann Wallblom; Katarina Uttervall; Johan Lund; Birgitta Stellan; Gösta Gahrton; Hareth Nahi; Evren Alici
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

6.  Epigenetic alterations in patients with type 2 diabetes mellitus.

Authors:  S Karachanak-Yankova; R Dimova; D Nikolova; D Nesheva; M Koprinarova; S Maslyankov; R Tafradjiska; P Gateva; M Velizarova; Z Hammoudeh; N Stoynev; D Toncheva; T Tankova; I Dimova
Journal:  Balkan J Med Genet       Date:  2016-07-09       Impact factor: 0.519

7.  Risk score based on ten lncRNA-mRNA expression predicts the survival of stage II-III colorectal carcinoma.

Authors:  Ruigang Diao; Xiaodong Mu; Tingting Wang; Shuqing Li
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

8.  Neuroserpin polymers cause oxidative stress in a neuronal model of the dementia FENIB.

Authors:  Noemi A Guadagno; Claudia Moriconi; Valerio Licursi; Emanuela D'Acunto; Paola S Nisi; Nicoletta Carucci; Antonella De Jaco; Emanuele Cacci; Rodolfo Negri; Giuseppe Lupo; Elena Miranda
Journal:  Neurobiol Dis       Date:  2017-03-28       Impact factor: 5.996

9.  A four-gene signature-derived risk score for glioblastoma: prospects for prognostic and response predictive analyses.

Authors:  Mianfu Cao; Juan Cai; Ye Yuan; Yu Shi; Hong Wu; Qing Liu; Yueliang Yao; Lu Chen; Weiqi Dang; Xiang Zhang; Jingfang Xiao; Kaidi Yang; Zhicheng He; Xiaohong Yao; Yonghong Cui; Xia Zhang; Xiuwu Bian
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

10.  Glucose availability determines silver nanoparticles toxicity in HepG2.

Authors:  Mariusz Zuberek; Dominika Wojciechowska; Damian Krzyzanowski; Sylwia Meczynska-Wielgosz; Marcin Kruszewski; Agnieszka Grzelak
Journal:  J Nanobiotechnology       Date:  2015-10-22       Impact factor: 10.435
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.